Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese Subjects: An Open-Label, Single-Center, First-in-Human Study

Background: Bencycloquidium bromide (BCQB) is a novel, potent and selective muscarinic M1/M3 receptor antagonist under development for the treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of BCQB in animals have been established in preclinical studies. However, no clinical pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Luning, Ding, Li, Wang, Yongqing, Zhou, Wenjia, Yan, Zhengyu, Sun, Weilin, Zhang, Hongwen, Ou, Ning, Chen, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585954/
https://www.ncbi.nlm.nih.gov/pubmed/22339483
http://dx.doi.org/10.2165/11599330-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585954/
https://www.ncbi.nlm.nih.gov/pubmed/22339483
http://dx.doi.org/10.2165/11599330-000000000-00000

Ejemplares similares